$2.28
+0.08
(+3.64%)▲
Insights on Codexis, Inc.
Revenue is down for the last 2 quarters, 21.32M → 9.27M (in $), with an average decrease of 56.5% per quarter
Netprofit is down for the last 2 quarters, -11.52M → -34.90M (in $), with an average decrease of 202.9% per quarter
In the last 1 year, Seagen, Inc. has given 76.6% return, outperforming this stock by 135.9%
In the last 3 years, Novo Nordisk A/s has given 20.7% return, outperforming this stock by 107.4%
4.39%
Downside
Day's Volatility :7.23%
Upside
2.98%
36.4%
Downside
52 Weeks Volatility :79.23%
Upside
67.34%
Period | Codexis, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 29.55% | 0.0% | 0.0% |
6 Months | -10.24% | 1.3% | 0.0% |
1 Year | -59.29% | -4.3% | -1.5% |
3 Years | -86.72% | 17.6% | -7.0% |
Market Capitalization | 172.5M |
Book Value | $1.32 |
Dividend Share | 0.0 |
Dividend Yield | 2.84% |
Earnings Per Share (EPS) | -1.21 |
PEG Ratio | -1.16 |
Wall Street Target Price | 5.83 |
Profit Margin | -110.41% |
Operating Margin TTM | -204.12% |
Return On Assets TTM | -20.9% |
Return On Equity TTM | -66.48% |
Revenue TTM | 74.0M |
Revenue Per Share TTM | 1.1 |
Quarterly Revenue Growth YOY | -73.1% |
Gross Profit TTM | 20.5M |
EBITDA | -59.4M |
Diluted Eps TTM | -1.21 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.18 |
EPS Estimate Next Year | -0.66 |
EPS Estimate Current Quarter | -0.32 |
EPS Estimate Next Quarter | -0.19 |
What analysts predicted
Upside of 155.7%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 50.0M | ↑ 2.43% |
Net Income | -23.0M | ↑ 168.71% |
Net Profit Margin | -45.97% | ↓ 28.45% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 60.6M | ↑ 21.13% |
Net Income | -10.9M | ↓ 52.7% |
Net Profit Margin | -17.95% | ↑ 28.02% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 68.5M | ↑ 12.98% |
Net Income | -11.9M | ↑ 9.72% |
Net Profit Margin | -17.43% | ↑ 0.52% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 69.1M | ↑ 0.87% |
Net Income | -24.0M | ↑ 101.17% |
Net Profit Margin | -34.77% | ↓ 17.34% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 104.8M | ↑ 51.69% |
Net Income | -21.3M | ↓ 11.37% |
Net Profit Margin | -20.31% | ↑ 14.46% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 138.6M | ↑ 32.3% |
Net Income | -33.6M | ↑ 57.86% |
Net Profit Margin | -24.24% | ↓ 3.93% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 38.4M | ↑ 8.68% |
Net Income | -2.6M | ↓ 68.41% |
Net Profit Margin | -6.87% | ↑ 16.77% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 34.5M | ↓ 10.25% |
Net Income | -10.0M | ↑ 278.48% |
Net Profit Margin | -28.99% | ↓ 22.12% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 30.4M | ↓ 11.88% |
Net Income | -12.6M | ↑ 26.15% |
Net Profit Margin | -41.5% | ↓ 12.51% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.0M | ↓ 57.26% |
Net Income | -22.6M | ↑ 79.43% |
Net Profit Margin | -174.22% | ↓ 132.72% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 21.3M | ↑ 64.25% |
Net Income | -11.5M | ↓ 49.05% |
Net Profit Margin | -54.04% | ↑ 120.18% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.3M | ↓ 56.49% |
Net Income | -34.9M | ↑ 202.94% |
Net Profit Margin | -376.29% | ↓ 322.25% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 53.6M | ↑ 50.43% |
Total Liabilities | 29.1M | ↑ 75.71% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 78.3M | ↑ 45.98% |
Total Liabilities | 22.0M | ↓ 24.42% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 149.1M | ↑ 90.43% |
Total Liabilities | 43.6M | ↑ 98.19% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 221.6M | ↑ 48.68% |
Total Liabilities | 51.5M | ↑ 18.34% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 246.4M | ↑ 11.16% |
Total Liabilities | 82.0M | ↑ 59.07% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 250.4M | ↑ 1.63% |
Total Liabilities | 105.6M | ↑ 28.79% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 235.0M | ↓ 0.13% |
Total Liabilities | 75.5M | ↓ 1.47% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 235.3M | ↑ 0.14% |
Total Liabilities | 81.2M | ↑ 7.48% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 250.4M | ↑ 6.42% |
Total Liabilities | 105.6M | ↑ 30.11% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 218.1M | ↓ 12.91% |
Total Liabilities | 92.1M | ↓ 12.83% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 206.8M | ↓ 5.19% |
Total Liabilities | 82.6M | ↓ 10.24% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 154.5M | ↓ 25.3% |
Total Liabilities | 62.9M | ↓ 23.82% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -8.8M | ↑ 224.44% |
Investing Cash Flow | -908.0K | ↑ 7.84% |
Financing Cash Flow | 21.7M | ↓ 4518.37% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -14.1M | ↑ 60.84% |
Investing Cash Flow | -2.8M | ↑ 204.63% |
Financing Cash Flow | 38.6M | ↑ 78.15% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.6M | ↓ 10.88% |
Investing Cash Flow | -3.7M | ↑ 32.5% |
Financing Cash Flow | 54.0M | ↑ 39.91% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -16.5M | ↑ 31.08% |
Investing Cash Flow | -5.7M | ↑ 56.83% |
Financing Cash Flow | 80.8M | ↑ 49.75% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -14.3M | ↓ 13.34% |
Investing Cash Flow | -21.4M | ↑ 272.69% |
Financing Cash Flow | 3.8M | ↓ 95.34% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 11.3M | ↓ 179.09% |
Investing Cash Flow | -13.6M | ↓ 36.62% |
Financing Cash Flow | -575.0K | ↓ 115.26% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.2M | ↓ 80.5% |
Investing Cash Flow | -2.2M | ↓ 77.98% |
Financing Cash Flow | 233.0K | ↓ 118.2% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 19.7M | ↓ 1004.81% |
Investing Cash Flow | -1.3M | ↓ 41.04% |
Financing Cash Flow | 133.0K | ↓ 42.92% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.9M | ↓ 75.08% |
Investing Cash Flow | 33.0K | ↓ 102.52% |
Financing Cash Flow | 339.0K | ↑ 154.89% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.2M | ↓ 287.35% |
Investing Cash Flow | -3.3M | ↓ 10051.52% |
Financing Cash Flow | 1.4M | ↑ 298.82% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -16.1M | ↑ 74.63% |
Investing Cash Flow | -1.6M | ↓ 52.16% |
Financing Cash Flow | 6.9M | ↑ 412.06% |
Sell
Neutral
Buy
Codexis, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Codexis, Inc. | 42.5% | -10.24% | -59.29% | -86.72% | -89.25% |
![]() Moderna, Inc. | 15.55% | -34.84% | -54.71% | -48.71% | 327.23% |
![]() Regeneron Pharmaceuticals, Inc. | 4.98% | 12.54% | 12.01% | 71.93% | 122.5% |
![]() Novo Nordisk A/s | -3.39% | 22.29% | 49.93% | 175.13% | 320.63% |
![]() Seagen, Inc. | 2.84% | 11.38% | 76.6% | 20.74% | 261.06% |
![]() Vertex Pharmaceuticals Incorporated | -5.0% | 4.8% | 12.15% | 56.05% | 101.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Codexis, Inc. | NA | NA | -1.16 | -1.18 | -0.66 | -0.21 | 0.03 | 1.32 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -12.72 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 23.18 | 23.18 | 1.75 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 41.18 | 41.18 | 4.02 | 2.67 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.38 | 26.38 | 0.5 | 15.04 | 0.23 | 0.14 | 0.0 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Codexis, Inc. | Buy | $172.5M | -89.25% | NA | -110.41% |
![]() Moderna, Inc. | Buy | $30.4B | 327.23% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $88.5B | 122.5% | 23.18 | 30.47% |
![]() Novo Nordisk A/s | Buy | $459.0B | 320.63% | 41.18 | 35.11% |
![]() Seagen, Inc. | Hold | $40.2B | 261.06% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.5B | 101.49% | 26.38 | 35.94% |
BlackRock Inc
Nantahala Capital Management, LLC
FMR Inc
Baillie Gifford & Co Limited.
Vanguard Group Inc
Telemark Asset Management, LLC
Codexis, Inc.’s price-to-earnings ratio stands at None
Read Morecodexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop
Organization | Codexis, Inc. |
Employees | 248 |
CEO | Dr. Stephen George Dilly MBBS, Ph.D. |
Industry | Process Industries |
Asymmetric Smart Alpha S&p 500 Etf
$2.28
+3.64%
Advisorshares Alpha Dna Equity Sentiment Etf
$2.28
+3.64%
Falcon's Beyond Global Inc
$2.28
+3.64%
Jaguar Global Growth Corporation I
$2.28
+3.64%
Missfresh Ltd
$2.28
+3.64%
Shuaa Partners Acquisition Corp I
$2.28
+3.64%
Rose Hill Acquisition Corp
$2.28
+3.64%
Partners Bancorp
$2.28
+3.64%
Bsquare Corp
$2.28
+3.64%